Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.79 Analyst target: $5.45 Upside: 592.94%
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.